| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1019922413 |
| P356 | DOI | 10.1186/AR3871 |
| P932 | PMC publication ID | 3446521 |
| P698 | PubMed publication ID | 22682496 |
| P5875 | ResearchGate publication ID | 225289891 |
| P50 | author | Rebecca Roberts | Q113363133 |
| Chris Frampton | Q89444867 | ||
| Lisa Stamp | Q63042017 | ||
| P2093 | author name string | John Highton | |
| Paul A Hessian | |||
| Jody Hazlett | |||
| P2860 | cites work | The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 |
| A simple salting out procedure for extracting DNA from human nucleated cells | Q27861086 | ||
| The PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis | Q28195442 | ||
| Much Ado about Adenosine: Adenosine Synthesis and Function in Regulatory T Cell Biology | Q30433245 | ||
| Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial | Q33308049 | ||
| Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. | Q34539873 | ||
| Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study | Q35605663 | ||
| Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3 adenosine receptor expression | Q35630047 | ||
| Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX. | Q36773117 | ||
| TNF-alpha upregulates the A2B adenosine receptor gene: The role of NAD(P)H oxidase 4. | Q36973962 | ||
| Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages | Q37008144 | ||
| A1 and A2 adenosine receptors in synovial cells from patients with rheumatic diseases | Q69422771 | ||
| Synovial and serum levels of methotrexate during methotrexate therapy of rheumatoid arthritis | Q69745928 | ||
| Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: A mechanism for methotrexate-induced nodulosis in rheumatoid arthritis | Q73491938 | ||
| Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis | Q80201783 | ||
| The compaction of DNA helices into either continuous supercoils or folded-fiber rods and toroids | Q40128387 | ||
| Inflammatory cytokines regulate function and expression of adenosine A(2A) receptors in human monocytic THP-1 cells. | Q40779392 | ||
| A new method for the isolation of deoxyribonucleic acids; evidence on the nature of bonds between deoxyribonucleic acid and protein | Q42954617 | ||
| Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate | Q43102130 | ||
| Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy | Q43180962 | ||
| Normalization of A2A and A3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor alpha but not methotrexate | Q43269361 | ||
| Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. | Q44278529 | ||
| Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study | Q44973310 | ||
| The anti-inflammatory target A(3) adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease. | Q46019649 | ||
| Inhibition of synoviocyte collagenase gene expression by adenosine receptor stimulation | Q46199674 | ||
| Cell-specific expression of TLR9 isoforms in inflammation. | Q54399769 | ||
| Overexpression of A3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of nuclear factor-kappaB in mediating receptor level. | Q54562922 | ||
| P433 | issue | 3 | |
| P921 | main subject | methotrexate | Q422232 |
| P304 | page(s) | R138 | |
| P577 | publication date | 2012-06-08 | |
| P1433 | published in | Arthritis Research and Therapy | Q15757229 |
| P1476 | title | Adenosine receptor expression in rheumatoid synovium: a basis for methotrexate action | |
| P478 | volume | 14 |
| Q39418010 | A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy |
| Q40957424 | ATIC 347C>G gene polymorphism may be associated with methotrexate-induced adverse events in south Indian Tamil rheumatoid arthritis |
| Q34035228 | Adenosine signaling during acute and chronic disease states |
| Q95654925 | Analysis of association of ADORA2A and ADORA3 polymorphisms genotypes/haplotypes with efficacy and toxicity of methotrexate in patients with Rheumatoid arthritis |
| Q39043220 | Are gene polymorphisms related to treatment outcomes of methotrexate in patients with rheumatoid arthritis? A systematic review and meta-analysis |
| Q54525909 | Association of disease severity with IL-1 levels in methotrexate-treated psoriasis patients. |
| Q53093606 | Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis. |
| Q34885098 | Distinct effects of methotrexate and etanercept on the B cell compartment in patients with juvenile idiopathic arthritis |
| Q54974227 | Inhibition of IL-17 and IL-23 in Human Keratinocytes by the A3 Adenosine Receptor Agonist Piclidenoson. |
| Q38991972 | Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. |
| Q42975335 | Multi-omic landscape of rheumatoid arthritis: re-evaluation of drug adverse effects |
| Q38195630 | Pharmacogenetics and pharmacogenomics for rheumatoid arthritis responsiveness to methotrexate treatment: the 2013 update |
| Q42367885 | Purinergic Signalling: Therapeutic Developments |
| Q37468714 | Purinergic signalling in the musculoskeletal system. |
| Q89619982 | Signaling of the Purinergic System in the Joint |
| Q92990019 | The Adenosine A2B Receptor Drives Osteoclast-Mediated Bone Resorption in Hypoxic Microenvironments |
| Q55383408 | The Polymorphism in ADORA3 Decreases Transcriptional Activity and Influences the Chronic Heart Failure Risk in the Chinese. |
| Q58765606 | The human lymph node microenvironment unilaterally regulates T-cell activation and differentiation |
Search more.